 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning Diamyd Medical AB
|
-
Diamyd executes agreement with US National Institutes of Health for a type 1 diabetes trial
(11/27/2007)
Diamyd Medical announced that it has executed a Clinical Trial Agreement with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for a planned clinical study with the DiamydŽ GAD-alum diabetes vaccine in 126 new onset type ...
-
Diamyd Medical outlicences Gene to Neurologix for treatment of Parkinson's disease
(08/09/2006)
Diamyd Medical AB has entered into a non-exclusive license agreement by which Neurologix, Inc., obtained rights to use the GAD65 molecule in its development of a therapeutic treatment for Parkinson's disease. Terms of the agreement include a license ...
-
Diamyd Medical appoints Protein Sciences for production of its lead therapeutic diabetes vaccine
(12/22/2005)
Diamyd Medical AB announced that is has reached an agreement with Protein Sciences Corporation, a biopharmaceutical service company, for production of Diamyd(TM), its lead therapeutic diabetes vaccine. Under the terms of the agreement, Protein ...
-
Diamyd Medical broadens diabetes pipeline with acquisition of Nurel Therapeutics
(12/15/2005)
Diamyd Medical AB emerged as a global biotechnology company as shareholders approved the acquisition of Nurel Therapeutics Inc at a General Assembly Meeting in Stockholm. The Pittsburgh-based biotech adds significantly to Diamyd Medical's pipeline ...
-
Diamyd aquires American biotechnology company Nurel Therapeutics, Inc.
(11/24/2005)
Diamyd Medical AB announced that it has agreed to acquire all of the outstanding shares in Nurel, a Pittsburgh PA-based biotechnology company. The merger is subject to approval by the board of directors of each company and their respective ...
-
Diamyd Provides Update on Negotiations to Acquire American Biotechnology Company
(11/11/2005)
Diamyd Medical AB announced that it is making considerable progress in the negotiations to acquire a small American biotechnology company. This acquisition target has clear overlapping interests with Diamyd's licensed GAD-technology platform in the ...
-
Dyamid's GAD gene is a potential therapeutic for reducing pain associated with Diabetes, Neuropathy and Cancer
(06/07/2005)
Diamyd Medical AB reported that the GAD gene can potentially be used for treatment of pain and neuropathy - common complications of diabetes and cancer. Diamyd Medical has an exclusive license for the GAD65 gene from the University of California in ...
-
Diamyd assigns Biovitrum development of production process for its diabetes drug GAD65
(04/06/2005)
Diamyd Medical AB and Biovitrum AB have signed an agreement covering the market adaptation of the production process for GAD65, Diamyd's product for the treatment of diabetes. The agreement means that Biovitrum is assigned the task of adapting the ...
Additional information
Diamyd Medical AB
Stockholm, Sweden
Company
|
|
|
|
|
|
Top
